BioNTech SE, the Mainz-based biotechnology firm known for its role in developing the COVID-19 vaccine Comirnaty, is pivoting its focus toward a robust oncology pipeline. As of June 2026, the company continues to advance its mRNA-based immunotherapies and targeted cancer treatments, aiming to translate fundamental research into clinical survival outcomes for patients worldwide.
How BioNTech is Expanding Its Oncology Portfolio
BioNTech operates with a strategy that combines three distinct therapeutic modalities: mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies. According to the company, these approaches are designed to target cancer cells with high precision. By combining these modalities, BioNTech seeks to create synergistic treatments that address various stages of cancer, ranging from the adjuvant setting to advanced, metastatic disease.
A major milestone in this strategy occurred in September 2025, when BioNTech reported that its antibody-drug conjugate (ADC) treatment, trastuzumab pamirtecan, met its primary endpoint in a phase 3 clinical trial. Conducted in China by partner Duality Biologics, the trial evaluated patients with unresectable or metastatic breast cancer who had previously undergone chemotherapy. According to BioNTech, this was the company’s first late-stage oncology drug to reach its primary endpoint in a phase 3 study.
What Is the Role of mRNA in Current Research?
BioNTech’s research is rooted in the belief that the immune system is the primary driver for treating cancer and infectious diseases. The company utilizes mRNA technology to instruct the immune system to recognize internal threats like cancer cells and external threats like viruses.
This platform was the foundation for the Comirnaty vaccine, developed in partnership with Pfizer, which became the first approved mRNA-based vaccine. Beyond infectious diseases, the company is now applying this expertise to oncology, developing therapies intended to improve or establish new standards of care. Among its priority programs is the bispecific antibody candidate BNT327, which BioNTech describes as a potential next-generation immuno-oncology backbone for a broad range of cancers.
Key Financial and Operational Context
As of the 2025 fiscal year, BioNTech reported revenue of €2.87 billion, with operating and net losses of €1.40 billion and €1.14 billion, respectively. Despite these figures, the company maintains a significant research infrastructure, employing 7,807 people globally as of 2025.
The company’s leadership, including co-founder and Chief Medical Officer Özlem Türeci, has emphasized the “enormous potential” of its oncology assets. Following the successful phase 3 results for trastuzumab pamirtecan in late 2025, the company and its partner, Duality Biologics, announced plans to engage with regulatory bodies, including the Center for Drug Evaluation in China, to file a biologics license application. BioNTech also indicated its intention to pursue similar regulatory submissions in the United States and the European Union.
What Happens Next for the Oncology Pipeline?
BioNTech’s future growth is tied to its ability to successfully navigate the regulatory landscape for its late-stage oncology candidates. With the successful trial of its first late-stage oncology drug, the company has demonstrated the feasibility of its combination strategy. Investors and the medical community are now looking toward the next steps for international regulatory filings and the continued development of the company’s broader portfolio of immunomodulators and targeted therapies. As the company continues to execute its combination strategy, it aims to establish curative approaches that address the full continuum of cancer care.